CF PHARMTECH (02652) has been awarded the 2026 Science and Technology Innovation Golden Bull Award, anchoring its global innovation strategy, and using inhalation formulation technology breakthroughs to redefine the future of respiratory therapy.

On September 6, 2026, the "2026 Xiamen Science and Technology Innovation Industry and Securities Development Conference and Securities Industry Golden Bull Award Ceremony," organized by China Securities Journal, was grandly held in Xiamen. CF PHARMTECH Co., Ltd. (02652) won the "Golden Bull Award for Technological Innovation" due to its systematic technological innovations in inhalation drug delivery, successful independent industrialization, and global innovative strategic layout. This award is a significant recognition from both the capital market and the industry for the companys path towards source innovation. It also validates CF PHARMTECH's innovation development strategy, which is rooted in China while looking towards the global market, aligning closely with the trend of driving high-quality development in the biopharmaceutical industry through new productivity. The Golden Bull Award, hosted by China's Xinhua News Agency-affiliated publication "China Securities Journal," has built a rigorous and objective evaluation system over more than 20 years, aiming to discover benchmark enterprises that deeply integrate technology and industry and empower the cultivation of new productivity. CF PHARMTECH has independently established a research platform for multi-formulation inhalation preparations and achieved several key technological breakthroughs in drug delivery systems, bringing innovative therapeutic methods based on new inhalation mechanisms to global patients, embodying the global strategic development path of innovative pharmaceutical companies. Depth of technology and industrial value: Strategic leap from import substitution to global source innovation CF PHARMTECH's innovative strategy has transitioned from local breakthroughs to global competition, building a core competency of "technology platform + global pipeline + global compliant commercialization." Era 1.0: Focusing on domestic needs, achieving import substitution for urgently needed clinical products, laying a solid groundwork for globalization In its early development, the company focused on respiratory diseases, such as asthma and COPD, which have significant clinical gaps in China, using independent research and development to break the long-term monopoly of foreign pharmaceutical companies in the inhalation preparation market. So far, six products have received approval from NMPA and FDA, with over 20 ongoing research pipelines across China, the U.S., and Europe. While enhancing access to medications for domestic patients, the company has established a complete industrial capability encompassing research and development, process manufacturing, global regulatory registration, and commercialization, laying a strong foundation for subsequent source innovation and product globalization. Era 2.0: Anchoring global innovation strategy, tackling source innovation, and laying out potential pioneering and best-in-class solutions Entering a new stage of development, CF PHARMTECH targets globally unmet clinical needs as the starting point for innovation, leveraging its controllable multi-formulation inhalation technology platform to tackle high-barrier frontier fields. The companys self-developed inhalable innovative drugs have entered the clinical stage, targeting globally challenging pulmonary diseases such as idiopathic pulmonary fibrosis and pulmonary arterial hypertension, creating treatment solutions with "first-in-class and best-in-class" potential. The company adheres to a global innovation vision that integrates drugs and devices while simultaneously developing inhalation delivery devices and bronchial interventional devices, creating synergies in the collaborative development of drugs and devices. The technological boundary continues to extend outward, with iterative advancements in cutting-edge platforms such as exhalation-driven nasal spray delivery systems, liposomal inhalation, and siRNA nucleic acid delivery. Additionally, it is pioneering the exploration of precise delivery via the "nose-brain pathway," expanding inhalation delivery technology into new avenues such as central nervous system diseases, thus breaking the traditional treatment boundaries of respiratory diseases. On the commercialization front, the company insists on parallel domestic and overseas operations, achieving overseas commercialization and regulatory breakthroughs in multiple countries, ensuring that the research pipeline is global-centered and that production meets global compliance standards, deeply implementing the philosophy of "integrating global capital and co-creating the future of industry." Looking to the future: Linking the world through innovation, assisting the China Meheco Group's industrial transformation and upgrading Winning the Golden Bull Award for Technological Innovation marks a new beginning. In the future, CF PHARMTECH will continue to uphold its corporate mission of "focusing on breathing, caring for life," further deepening its global innovation strategy, leveraging capital market empowerment, and accelerating the clinical transformation of its source innovation pipeline. On one hand, it will continually provide respiratory treatment solutions that address global clinical pain points, enabling more patients worldwide to benefit from high-quality inhalation innovative therapies; on the other hand, it will continue to leverage its multi-formulation inhalation platform advantages to enhance the domestic capacity for high-end complex preparations, contributing to the transformation and upgrading of China's biopharmaceutical industry.